In exercise of the powers conferred by section 9, read with section 76 of the Narcotic Drugs and Psychotropic Substances Act

## Policy Analysis Report: Narcotic Drugs and Psychotropic Substances Amendment Rules, 2021 **1. Executive Summary:** This report analyzes the *Narcotic Drugs and Psychotropic Substances Amendment Rules, 2021*, as published in the Gazette of India on March 23, 2021. This amendment modifies the *Narcotic Drugs and Psychotropic Substances Rules, 1985*, specifically updating Schedule I, which lists psychotropic substances. The key finding is the addition of "DOC (4-Chloro-2,5-dimethoxyamphetamine)" and its salts/preparations to the list of controlled psychotropic substances. This amendment likely aims to regulate and control the use and distribution of this specific substance, impacting manufacturers, distributors, and users of psychotropic substances. **2. Introduction:** The purpose of this report is to provide an informative analysis of the *Narcotic Drugs and Psychotropic Substances Amendment Rules, 2021*, based solely on the text provided in the Gazette of India publication. This analysis will focus on the amendment's objectives, key changes, affected parties, inferred implementation aspects, and potential impact. **3. Policy Overview:** * **Amendment to:** *Narcotic Drugs and Psychotropic Substances Rules, 1985* * **Core Objective(s):** The core objective of this amendment, as inferred from the text, is to update and expand the list of controlled psychotropic substances under the *Narcotic Drugs and Psychotropic Substances Rules, 1985*. This update likely aims to align the regulations with current trends in drug use and abuse, and to control potentially harmful substances. **4. Background and Rationale:** As this is an amendment, the background concerns the reasons for altering the existing *Narcotic Drugs and Psychotropic Substances Rules, 1985*. The rationale for this specific amendment appears to be the need to include "DOC (4-Chloro-2,5-dimethoxyamphetamine)" and its salts/preparations within the list of controlled substances. This addition suggests that this substance has been identified as a potential threat, requiring regulation to prevent misuse and protect public health and safety. Without this amendment, DOC would not be subject to the controls outlined in the original rules. **5. Key Provisions / Changes:** This amendment introduces the following changes to the *Narcotic Drugs and Psychotropic Substances Rules, 1985*: * **Specific Part Changed:** Schedule I, under heading II. Psychotropic substances. * **New Rule/Provision:** The amendment substitutes serial number 33 in Schedule I with the following entries: * "33 DOC 4-Chloro-2,5-dimethoxyamfetamine" * "34 Salts and preparation of above" * **Difference/Effect of the Change:** This change adds DOC (4-Chloro-2,5-dimethoxyamphetamine) and its salts/preparations to the list of controlled psychotropic substances. This means that the manufacture, possession, sale, purchase, transportation, import, export, and use of DOC and its salts/preparations will now be subject to the regulations and restrictions outlined in the *Narcotic Drugs and Psychotropic Substances Act, 1985* and related rules. Previously, these activities were not regulated under this act, allowing for potential unregulated use and distribution. **6. Target Audience and Stakeholders:** The target audience and stakeholders directly affected by this amendment include: * Manufacturers of pharmaceutical products and chemicals. * Distributors and suppliers of chemicals and psychotropic substances. * Researchers and laboratories using psychotropic substances for scientific purposes. * Law enforcement agencies responsible for enforcing drug control laws. * Healthcare professionals involved in the treatment of substance abuse. * Individuals who may be using or considering using DOC (4-Chloro-2,5-dimethoxyamphetamine). **7. Implementation Aspects (Inferred):** * **Responsible Agency/Bodies:** The Ministry of Finance, Department of Revenue, is responsible for enacting the amendment. Implementation and enforcement would likely involve various drug control agencies at the central and state levels. * **Timelines/Procedures:** The amendment came into force on the date of its publication in the Official Gazette (March 23, 2021). Specific procedures for compliance will be governed by the existing *Narcotic Drugs and Psychotropic Substances Rules, 1985* and related guidelines, now applicable to DOC. These procedures are not detailed in the amendment itself. * **Implementation specific to changes:** Manufacturers and distributors will need to obtain the necessary licenses and permits to handle DOC. Law enforcement will need to update their drug testing and investigation procedures to include DOC. **8. Expected Outcomes / Impact of Changes:** The likely intended outcome of this amendment is to: * Reduce the availability and misuse of DOC (4-Chloro-2,5-dimethoxyamphetamine) and its salts/preparations. * Prevent potential harm to public health and safety associated with the unregulated use of this substance. * Provide law enforcement agencies with the necessary legal framework to combat the illegal manufacture, distribution, and use of DOC. * Increase regulatory burden on entities involved in handling psychotropic substances The potential impact of the amendment includes increased costs for compliance for legitimate manufacturers and distributors, as well as potential disruptions to research activities involving controlled substances. **9. Conclusion:** The *Narcotic Drugs and Psychotropic Substances Amendment Rules, 2021* represent a significant update to the existing regulatory framework for controlled substances in India. By adding DOC (4-Chloro-2,5-dimethoxyamphetamine) and its salts/preparations to Schedule I, the government aims to control the availability and misuse of this substance, thereby protecting public health and safety. This amendment necessitates compliance from various stakeholders, including manufacturers, distributors, researchers, and law enforcement agencies. This amendment reinforces the government's commitment to addressing emerging drug trends and strengthening drug control measures.

Key Entities Referenced